drug_type
RELEVANT_DRUG
intervention_type
Biologic
drug_description
An intravenous bispecific T‑cell–engager monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells to redirect T‑cell cytotoxicity against myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, bringing T cells into proximity to activate CD3/TCR signaling, form an immune synapse, and induce perforin/granzyme-mediated cytotoxic killing of BCMA-positive myeloma cells.
drug_name
Linvoseltamab
nct_id_drug_ref
NCT06376526